drugset / Trial / NCT03227562

Is Initial Response to Low Dose Risperidone Predictive for Outcome in Anxiety?

NCT03227562

Phase 3 Terminated 120 enrolled Marion Trousselard
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Risperidone at low dosage is often used as treatment of acute anxiety symptom. However, patients may be either responder or not. Here we hypothesized that the early response to a low dose of risperidone is predictive to risperidone efficiency. Subjects with acute anxiety symptoms (Hospital anxiety depression scale) and risperidone prescription would be proposed to be enrolled in the study. A check-up is made at D0, then the subjects begin the treatment (0.5mg risperidone). The same check-up is carried out on the following day (D1). The subjects fulfil a last check-up 12 week after the beginning of treatment (W12). During the D1-W12, the psychiatrist may changes the treatment.

Timeline

Start
2017-09-01
Primary completion
2021-09-01
Completion
2021-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Risperidone Other / unclassified 0.5 mg

Indications